The first patient in a Phase 2a trial of BOS-580 as a treatment for nonalcoholic steatohepatitis (NASH) was recently dosed. Boston Pharmaceuticals, the developer of the drug, aims to address…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Rare disease patients often face obstacles when it comes to the different aspects of care, whether that's diagnosis, screening, or management. Recent research from Baylor College of Medicine investigated the…
Auto-Brewery Syndrome Auto-brewery syndrome is also known as gut fermentation syndrome. It occurs when fungi or bacteria within the gut produce ethanol by endogenous fermentation. Several different strains may be…
According to a recent report in Medical Xpress, over twenty studies have indicated escalating events of nonalcoholic fatty liver disease (NAFLD) in children worldwide. In the United States, NAFLD heads…
According to Yahoo Finance, D&D Pharmatech has initiated dosing in their Phase 1 trial of DD01, a treatment for nonalcoholic fatty liver disease (NAFLD) and diabetes in obese patients. As…
Fatty liver disease, which can be caused by alcohol consumption or can be unrelated (nonalcoholic fatty liver disease/NAFLD), belongs to a larger group of conditions that have been labeled as…
According to a study from hindawi.com, the serum glycocholic acid (GCA) to total bile acid (TBA) ratio can be used to identify people living with nonalcoholic fatty liver disease (NAFLD).…
by Lauren Taylor from In The Cloud Copy Nonalcoholic fatty liver disease, or NAFLD, and nonalcoholic steatohepatitis, or NASH, are two conditions affecting the liver that plague millions of Americans…
Target RWE, an innovative health evidence solutions company based in Durham, North Carolina recently announced its current data from the study of nonalcoholic steatohepatitis (NASH) via PRNewswire. The study, entitled…
This past week, Target RWE announced data from its TARGET-NASH study, designed to better understand differences in health outcomes for patients with nonalcoholic fatty liver disease (NAFLD). According to their…
by Natalie Homan from In The Cloud Copy A review article published in Endocrinology in August of this year highlights the fact that a female's risk of developing nonalcoholic fatty…
by Danielle Bradshaw from In The Cloud Copy It’s possible for fat to end up stored inside of the liver due to either obesity, diabetes, certain medications, or high cholesterol.…
Biopharmaceutical company Theratechnologies Inc. recently announced that its therapy candidate tesamorelin is effective in the treatment of HIV-associated nonalcoholic steatohepatitis (NASH). According to new data, published in JCI Insight, tesamorelin…
By Lauren Thayer from In The Cloud Copy Nonalcoholic fatty liver disease or NAFLD is a term used to describe a range of conditions in which a patient’s liver has…
When it comes to researching and finding treatments for rare diseases, funding plays a crucial role. Recently, the Medical Research Future Fund (MRFF) Stem Cell Therapies Mission presented Monash…
In a Business Wire press release, the Canadian NASH Network (CanNASH) shared the results of a recent study predicting a severe increase in cases of nonalcoholic fatty liver disease…
Axcella, a biotechnology company based out of Cambridge, Massachusetts, has released the results of AXA1125-003. According to Biotech 365, this study showed positive results for those with non-alcoholic fatty liver…
As originally reported in News Medical, a new study suggests that gastric bypass bariatric surgery may be the most effective treatment for non-alcoholic fatty liver disease (NAFLD). This disorder currently…
According to a story from hepmag.com, a panel of experts is recommending a name change for non-alcoholic fatty liver disease (NAFLD) and is instead proposing that the condition be called…
It's common knowledge that your Corona is doing your liver no favours. Heavy alcohol consumption isn’t great for your health. Reported in Cell Metabolism, new research gets more specific: the…
Thirty-five percent of all Americans and almost 25% of the entire world population may be unknowingly suffering from a "silent killer." Nonalcoholic fatty liver disease or NAFLD is occurs…
Nonalcoholic fatty liver disease (NAFLD) is a condition in which the buildup of fat in the liver poses health concerns. Nonalcoholic Steatohepatitis (NASH) is a more severe, and more rare…
Nonalcoholic fatty liver disease (NAFLD) is exactly what it sounds like. It's caused by a buildup of fat cells in the liver, resulting in many complications caused by the thickening…
In the UK, Newcastle University and Pfizer are collaborating on a $39.9 million-dollar funded project aimed at developing greater tools for testing patients at the most risk for non-alcoholic fatty…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
